Your browser doesn't support javascript.
loading
The Global Impact of Hepatitis B Vaccination on Hepatocellular Carcinoma.
Flores, Joan Ericka; Thompson, Alexander J; Ryan, Marno; Howell, Jessica.
Afiliación
  • Flores JE; Department of Gastroenterology, St. Vincent's Hospital Melbourne, Fitzroy, VIC 3065, Australia.
  • Thompson AJ; Department of Medicine, University of Melbourne, Parkville, VIC 3010, Australia.
  • Ryan M; Department of Gastroenterology, St. Vincent's Hospital Melbourne, Fitzroy, VIC 3065, Australia.
  • Howell J; Department of Medicine, University of Melbourne, Parkville, VIC 3010, Australia.
Vaccines (Basel) ; 10(5)2022 May 17.
Article en En | MEDLINE | ID: mdl-35632549
ABSTRACT
Over 1.5 million preventable new hepatitis B infections continue to occur each year and there are an estimated 296 million people living with chronic hepatitis B infection worldwide, resulting in more than 820,000 deaths annually due to liver cirrhosis and hepatocellular carcinoma (HCC). Hepatitis B vaccination remains the cornerstone of public health policy to prevent HCC and a vital component of the global hepatitis B elimination response. The WHO has set a 90% vaccination target to achieve hepatitis B elimination by 2030; however, there is wide variability in reported birth dose coverage, with global coverage at only 42%. In this review, we outline the global trends in hepatitis B vaccination coverage and the impact of hepatitis B vaccination on HCC incidence and discuss the challenges and enabling factors for achieving WHO 2030 hepatitis B vaccination coverage targets.
Palabras clave

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Vaccines (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Vaccines (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Australia